Clinical trialNCT07148739RecruitingPhase 4Interventional

Ensuring Access to Optimal Therapy in CF: The ENACT Study

SponsorArkansas Children's Hospital Research InstituteEnrollment100Cystic Fibrosis (CF)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Jennifer S Guimbellot, Medical Degree and License
Arkansas Children's Hospital Research Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

the University of Alabama at Birmingham
Birmingham, Alabama, United States
Recruiting
Arkansas Children'S Hospital
Little Rock, Arkansas, United States
Jennifer S Guimbellot, Medical Degree and License
Recruiting
University of Washington
Seattle, Washington, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Elexacaftor / ivacaftor / tezacaftor

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Jun 2025
Primary completion: 31 Dec 2030
Completion: 31 Dec 2030
Last update posted: 2 Jun 2026
Registered enrollment: 100
Registry id: NCT07148739

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.